cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi.
Biochemical and physiological studies have implicated cAMP and cAMP-dependent protein kinase (PKA) in a plethora of essential cellular processes. Here we show that yeast cells partially depleted of PKA activity (due to a tpkw mutation) and bearing a lesion in a Golgi-localized Ca2+ pump (Pmr1), arrest division with a small bud. The bud morphology of the arrested tpk1w pmr1 mutant cells is characteristic of cells in S phase; however, the terminal phenotype of processes such as DNA replication and nuclear division suggests arrest at the G2/M boundary. This small bud, G2-arrest phenotype is similar to that of strains with a defect in cell wall biosynthesis (pkc1) or membrane biogenesis (och1); however, the biochemical defect may be different since the tpk1w pmr1 double mutants retain viability. The growth defect of the tpk1w pmr1 mutant can be alleviated by preventing the increase in cellular cAMP levels that is known to be associated with a decrease in PKA activity, or by supplementing the medium with millimolar amounts of Ca2+. Although the biochemical consequences of this increase in cAMP concentration are not known, the small-bud phenotype of the double mutant and the known protein processing defect of the pmr1 lesion suggest that the localization or function of some membrane component might be compromised and susceptible to perturbations in cellular cAMP levels. One candidate for such a protein is the cAMP-binding membrane ectoprotein recently described in yeast.
Hartley
A D
AD
Department of Molecular Cancer Biology, Duke University Medical Center, Durham NC 27710, USA.
Bogaerts
S
S
Garrett
S
S
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000235:genetics; D019703:Calcineurin; D002118:Calcium / Q000378:metabolism*; D000252:Calcium-Transporting ATPases / Q000235:genetics; D002148:Calmodulin-Binding Proteins / Q000502:physiology; D000242:Cyclic AMP / Q000502:physiology*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000235:genetics / Q000502:physiology; D054677:Cyclic Nucleotide Phosphodiesterases, Type 1; D004271:DNA, Fungal / Q000096:biosynthesis; D016195:G2 Phase; D005800:Genes, Fungal / Q000235:genetics; D005804:Genes, Lethal / Q000235:genetics; D016153:Genes, Suppressor; D006056:Golgi Apparatus / Q000378:metabolism*; D009154:Mutation; D010641:Phenotype; D010749:Phosphoprotein Phosphatases / Q000502:physiology; D010727:Phosphoric Diester Hydrolases; D011493:Protein Kinase C / Q000235:genetics / Q000502:physiology; D012441:Saccharomyces cerevisiae / Q000187:drug effects / Q000201:enzymology / Q000235:genetics / Q000254:growth & development*; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000494:pharmacology; D013696:Temperature
D002148:Calmodulin-Binding Proteins; D004271:DNA, Fungal; C058028:immunomycin; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; D019703:Calcineurin; D010749:Phosphoprotein Phosphatases; D010727:Phosphoric Diester Hydrolases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054677:Cyclic Nucleotide Phosphodiesterases, Type 1; D000252:Calcium-Transporting ATPases; D002118:Calcium; D016559:Tacrolimus